1. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86–9.
2. Aspord C et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD41 T cells that facilitate tumor development. J Exp Med 2007; 204: 1037–47.
3. Austyn JM. Dendritic cells. Curr Opin Hematol 1998; 5: 3–15.
4. Berntsen A, Trepiakas R, Wenandy L et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008; 31: 771–80.
5. Binder RJ, Kelly JB, Vatner RE, Srivastava PK. Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins. J Immunol 2007; 179: 7254–61.
6. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465–72.
7. Brossart P et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96: 3102–8.
8. Caux C et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994; 180: 1841–7.
9. Caux C et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF a.  Adv Exp Med Biol 1997; 417: 21–5.
10. Cella M et al. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells see comments. Nature 1997; 388: 782–7.
11. Cella M et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747–52.
12. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10–6.
13. Chapuis F et al. Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol 1997; 27: 431–41.
14. Conti L et al. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 2005; 174: 252–60.
15. De Vleeschouwer S, Fieuws S, Rutkowski S et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14: 3098–104.
16. De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63: 12–7.
17. De Vries IJ, Lesterhuis WJ, Scharenborg NM et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9: 5091–100.
18. Dercamp C, Chemin K, Caux C et al. Distinct and overlapping roles of interleukin-10 and CD251 regulatory T cells in the inhibition of antitumor CD8 Tcell responses. Cancer Res 2005; 65: 8479–86.
19. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: Balancing immunity and tolerance. Cell Death Differ 2008; 15: 39–50.
20. Dolan BP, Gibbs KD, Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+T cells. J Immunol 2006; 177: 6018–24.
21. Draube A, Klein-Gonza´lez N, Mattheus S et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE 2011; 6 (4): e18801.
22. Ferlazzo G, Tsang ML, Moretta L et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 343–51.
23. Fernandez NC et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 405–11.
24. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent anti-tumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482–7.
25. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475–80.
26. Flamand V et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24: 605–10.
27. Fong L et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98: 8809–14.
28. Fonseca C, Dranoff G. Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res 2008; 14: 1603–8.
29. Freeman GJ et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027–34.
30. Gerosa F, Baldani-Guerra B, Nisii C et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 327–33.
31. Gough MJ, Ruby CE, Redmond WL et al. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 2008; 68: 5206–15.
32. Grouard G et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185: 1101–11.
33. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001; 166: 3717–23.
34. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245–87.
35. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro-Oncology 2011; 13 (1): 3–13.
36. Hermans IF et al. NKT cells enhance CD41 and CD81 T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171: 5140–7.
37. Hildenbrand B, Sauer B, Kalis O et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pretreated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells – a pilot study. Prostate 2007; 67: 500–8.
38. Hilkens CM et al. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997; 90: 1920–6.
39. Holtl L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002; 8: 3369–76.
40. Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30: 1–15.
41. Hsu FJ et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52–8.
42. Inaba K et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994; 180: 1849–60.
43. Jiang W et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375: 151–5.
44. Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001; 93: 243–51.
45. Kalinski P et al. Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol 2009; 5 (3): 379–90.
46. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–22.
47. Kleijmeer MJ et al. MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. J Immunol 1995; 154: 5715–24.
48. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297–39.
49. Lacy MQ, Mandrekar S, Dispenzieri A et al. Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol 2009; 84 (12): 799–802.
50. Lanzavecchina A. Mechanisms of antigen uptake for presentation. Curr Opin Immunol 1996; 8: 348–54.
51. Le Bon A, Durand V, Kamphuis E et al. Direct stimulation of T cells by type I IFN enhances the CD8+T cell response during cross-priming. J Immunol 2006; 176: 4682–9.
52. Le Bon A, Etchart N, Rossmann C et al. Cross-priming of CD8+T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009–15.
53. Leslie DS et al. CD1-mediated g/d T cell maturation of dendritic cells. J Exp Med 2002; 196: 1575–84.
54. Lin ML, Zhan Y, Villadangos JA, Lew AM. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol 2008; 86: 353–62.
55. Liu C, Lou Y, Lizee G et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008; 118: 1165–75.
56. Lodge PA et al. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000; 60: 829–33.
57. Macatonia SE et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+T cells. J Immunol 1995; 154: 5071–9.
58. Mackall CL, Rhee EH, Read EJ et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008; 14 (15): 4850–8.
59. Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18: 3964–73.
60. Martin-Fontecha A, Sebastiani S, Hopken UE et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003; 198: 615–21.
61. Mayordomo JI et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. Nat Med 1995; 1: 1297–302.
62. Miyasaka M, Tanaka T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat Rev Immunol 2004; 4: 360–70.
63. Mohamadzadeh M et al. Dendritic cells produce macrophage inflammatory protein-1 g, a new member of the CC chemokine family. J Immunol 1996; 156: 3102–6.
64. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117: 1147–54.
65. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005; 202: 203–7.
66. Neijssen J, Herberts C, Drijfhout JW et al. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 2005; 434: 83–8.
67. Norbury CC, Basta S, Donohue KB et al. CD8+T cell cross-priming via transfer of proteasome substrates. Science 2004; 304: 1318–21.
68. Paglia P et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo (see comments). J Exp Med 1996; 183: 317–22.
69. Palucka AK et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD81 T-cell immunity. J Immunother 2006; 29: 545–57.
70. Palucka AK et al. Single injection of CD341 progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother 2003; 26: 432–9.
71. Palucka AK et al. Spontaneous proliferation and type 2 cytokine secretion by CD41 T cells in patients with metastatic melanoma vaccinated with antigen-pulsed dendritic cells. J Clin Immunol 2005; 25: 288–95.
72. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008; 205: 825–39.
73. Pierre P et al. Developmental regulation of MHC class II transport in mouse dendritic cells see comments. Nature 1997; 388: 787–92.
74. Pure E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol 2005; 6: 1207–10.
75. Regnault A et al. Fcg receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189: 371–80.
76. Reichardt VL et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study. Blood 1999; 93: 2411–9.
77. Reid CD. The dendritic cell lineage in haemopoiesis. Br J Haematol 1997; 96: 217–23.
78. Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 1993; 178: 509–19.
79. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther 2002; 2: 57–78.
80. Ribas A, Comin-Anduix B, Chmielowski B et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009; 15 (19): 6267–76.
81. Rieser C et al. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 2000; 63: 151–9.
82. Rissoan MC et al. Reciprocal control of T helper cell and dendritic cell differentiation see comments. Science 1999; 283: 1183–6.
83. Robert C, Klein C, Cheng G et al. Gene therapy to target dendritic cells from blood to lymph nodes. Gene Ther 2003; 10: 1479–86.
84. Romani N et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83–93.
85. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J Exp Med 1994; 179: 1109–18.
86. Sallusto F et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products see comments. J Exp Med 1995; 182: 389–400.
87. Sampson JH, Archer GE, Mitchell DA et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiform. Molecular Cancer Therapeut 2009; 8 (10): 2773–9.
88. Schadendorf D et al. Dacarbazine (DTIC) versus vaccination with autologous peptidepulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563–70.
89. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985; 161: 526–46.
90. Schwaab T, Schwarzer A, Wolf B et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 2009; 15: 4986–92.
91. Shortman K, Caux C. Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells 1997; 15: 409–19.
92. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloidderived suppressor cells. Cancer Res 2007; 67: 4507–13.
93. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894–903.
94. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089–94.
95. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. J Exp Med 1973; 137: 1142–62.
96. Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 1978; 75: 5132–6.
97. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Ann Rev Immunol 2003; 21: 685–711.
98. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419–26.
99. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99: 351–8.
100. Terabe M et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515–20.
101. Terabe M et al. Transforming growth factorbeta production and myeloid cells are an effector mechanism through which CD1drestricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741–52.
102. Thomas-Kaskel AK, Zeiser R, Jochim R et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006; 119: 2428–34.
103. Thurner B et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669–78.
104. Tuyaerts S, Aerts JL, Corthals J et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007; 56: 1513–37.
105. van Tendeloo VF, de Velde AV, van Driessche A et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. PNAS 2010; 107 (31): 13 824–9.
106. Verdijk P, Aarntzen EH, Lesterhuis WJ et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009; 15: 2531–40.
107. Vetvicka V, Holub M. Phagocytic activity of peritoneal and omental macrophages of athymic nude mice. Immunol Invest 1988; 17: 531–41.
108. von Andrian UH, Memper TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003; 3: 867–78.
109. von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 2006; 107: 2786–9.
110. Wakkach A, Fournier N, Brun V et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18: 605–17.
111. Wierecky J, Muller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006; 66: 5910–8.
112. Zeelenberg IS, Ostrowski M, Krumeich S et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 2008; 68: 1228–35.
113. Zhou LJ, Tedder TF. A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. Blood 1995; 86: 3295–301.
114. Zitvogel L et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 co-stimulation, and T helper cell 1-associated cytokines (see comments). J Exp Med 1996; 183: 87–97.
115. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295–307.

М.А.Шевцов1–3, В.А.Хачатрян2, О.В.Галибин3, Б.А.Маргулис1

1 Институт цитологии РАН, Санкт-Петербург
2 Российский нейрохирургический институт им. проф. А.Л.Поленова, Санкт-Петербург
3 Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова

________________________________________________

M.A.Shevtsov, W.A.Khachatryan, O.V.Galibin, B.A.Margulis